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Abstract: The role of radiotherapy in the treatment of thymoma and
thymic carcinoma has been evaluated by many investigators over the
past two decades. The low incidence of these neoplasms has limited
most published studies to small series spanning long time intervals
or population-based studies. The exact indications and protocols for
the use of radiotherapy as a part of the multidisciplinary approach to
thymoma and thymic carcinoma are still unclear. However, a review
of recent literature shows potential beneﬁts for certain patients based
on stage and grade of disease as well as the extent of surgical
resection.
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B
ecause of the sensitivity of thymoma and thymic carci-
noma to radiation therapy, there is much interest in the
role of radiotherapy (RT) in the treatment of these rare
neoplasms. Although it is the most common anterior medi-
astinal compartment neoplasm (Figure 1),1 low incidence and
indolent natural history of the disease have made the work of
developing deﬁnitive recommendations for RT in the multi-
disciplinary approach to the treatment of thymic neoplasms
difﬁcult. In addition, the rapid advances in the delivery of RT
make it difﬁcult to evaluate the potential beneﬁt of current
treatment practices using data collected over several decades.
Currently, no domestic randomized prospective clinical trials
evaluating the role of adjuvant RT after complete resection of
thymoma or thymic carcinoma have been published. How-
ever, retrospective analysis using the Surveillance, Epidemi-
ology, and End Results (SEER) database as well as multiple
small case series show potential for the use of adjuvant RT
for the treatment of selected subpopulations of patients with
thymoma and thymic carcinoma.
Complete surgical resection provides an 82% 7-year
survival rate, whereas incomplete resection and biopsy alone
are associated with 71 and 26%, respectively.2 Therefore, the
mainstay of treatment for thymoma and thymic carcinoma
without unresectable/metastatic disease has been en bloc
resection of the tumor and adjacent involved structures.3
There is a potential role for both RT and chemoradiotherapy
to prevent recurrence for patients in whom a complete sur-
gical resection is not possible.
RT FOR THYMOMA
Some investigators in the late 1980s recommended
adjuvant RT for all thymic neoplasms regardless of stage or
completeness of resection.4,5 More recent studies have called
this practice into question, and current work is focused on the
beneﬁt of RT for patients stratiﬁed by tumor stage and
resection characteristics. Awad et al.6 performed a longitudi-
nal study of patients with Masaoka stage I thymomas (which
are completely encapsulated) who underwent complete resec-
tion and followed up for 32 years founda2t o3 %recurrence
rate, suggesting that adjuvant RT is unlikely to improve the
prognosis in this population of patients. Furthermore, the only
randomized prospective trial performed to date, a small (n 
29) series from Peking Union Medical College, demonstrated
no survival beneﬁt to RT (88% 10-year survival) compared
with surgery alone (92% 10-year overall survival) in
Masaoka stage I patients.7
Several other investigators also have data to suggest
adjuvant RT provides no beneﬁt for localized disease but
potentially beneﬁts Masaoka stage II and III8–13 and patients
receiving incomplete resections.8,10,14 In higher stage disease,
the beneﬁt of adjuvant RT may be more readily detectable. A
population-based domestic survival analysis of malignant
thymoma analyzing the SEER registry data (n  599) re-
vealed signiﬁcant overall survival beneﬁt from adjuvant RT
for a population comparable with Masaoka stage II.13 In a
more recent retrospective study using SEER registry data
(n  901), adjuvant RT provided no advantage in terms of
overall survival for patients with Masaoka stage I thymoma
and thymic carcinoma; however, signiﬁcant increase in over-
all survival was seen in patients with Masaoka stage II and III
disease, especially when surgery was nonextirpative.15 How-
ever, the SEER registry data included is not coded for
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consistent histopathologic criteria,13 radiation dose, number
of fractions, or elapsed days in the treatment course.15 This
limits the further reﬁnement of selection criteria that are
possible from SEER data. A recent retrospective study (n 
175) has also corroborated the data from these population-
based studies (Table 1).16
In addition, there are data from smaller, mostly insti-
tutional series to suggest survival beneﬁt via reduction of
recurrences both in the ﬁeld of radiation and secondary
distant progression with adjuvant RT.2,17–19 Although not
statistically signiﬁcant, a study of 68 patients by Curran et
al.18 showed that local recurrence reaches 47% at 5 years in
patients with stage II and III disease after an R0 resection
without adjuvant RT, whereas no recurrence was noted after the
addition on adjuvant RT. Likewise, of the 33 patients receiving
adjuvant RT, Urgesi et al.17 showed no in ﬁeld recurrences and
three out of ﬁeld recurrences, lending credence to the efﬁcacy of
local control with adjuvant management.
However, several contrasting datasets have also been
presented, with countervailing ﬁndings regarding RT utiliza-
tion. In one of the largest series to date, Kondo and Monden14
presented international report of 1000 pooled thymoma
patients, including 247 stage II cases, showing no difference
between surgery alone and adjuvant RT. A smaller domestic
report at the University of Pennsylvania of 167 patients
undergoing surgical resection of thymoma showed no beneﬁt
from adjuvant RT in margin negative stage II disease.20
Several other studies showed no decrease in local or distant
recurrence after R0 resection for stage III thymoma with
adjuvant RT,21–24 and Rufﬁni et al.25 actually showed worse
outcomes with the addition of adjuvant RT. Another recent
study of 41 thymoma patients actually showed a signiﬁcantly
longer total survival time in patients with stage II disease who
did not receive adjuvant RT.26 Likewise, a meta-analysis
published in 2009 by Korst et al.27 used data on 592 patients
obtained from 13 of 22 retrospective cohort studies and
showed no beneﬁt of adjuvant RT on recurrence rates after
complete resection of stage II and/or III thymic epithelial
tumors. Consequently, the use of radiation remains an area of
debate and institutional norms.
However, adjuvant RT is widely believed to be the
standard of care for residual disease after incomplete resec-
tions of stage III and IV disease. Curran et al.18 also showed
no mediastinal failures after radiation in 26 patients with
stage III thymomas and 79% recurrence after 5 years without
adjuvant RT. Other studies had similar ﬁndings with low
mediastinal recurrence after treatment with adjuvant RT.17,19
Many of the published retrospective studies focus on
the beneﬁts of adjuvant RT in terms of survival and recur-
rence based on stratiﬁcation by Masaoka stage. More recent
studies have focused World Health Organization (WHO) cell
type as a factor in establishing a good candidate group for
adjuvant RT. In 2009, Utsumi et al.28 published a retrospec-
tive study of 324 patients who underwent resection of a
thymoma in which 119 were treated with adjuvant RT. When
examined based on WHO cell type and Masaoka staging,
they showed that patients with stage I and II thymoma as well
as WHO types A, AB, and B1 should not receive adjuvant
RT. Also, no signiﬁcant difference in actuarial disease-spe-
ciﬁc survival rates were found in patients with stage III and
IV disease or WHO cell types B2 and B3 who were and were
not treated with adjuvant RT.28
Although the dose–response relationship for adjuvant
RT is as controversial as the indication(s), RT treatment
regimens for thymoma traditionally used doses ranging from
30 to 60 Gy in 1.8 to 2.0 Gy fractions, which were delivered
over 3 to 6 weeks.5,16–18,21,29–36 It was thought that 40 to 45
Gy is sufﬁcient for control of completely resected or micro-
scopic residual disease,37 but in a retrospective study of 175
patients, Zhu et al.16 showed that increasing the dose slightly
to 50 Gy might be beneﬁcial. Their data suggested that RT
dose 50 Gy is a prognostic factor for 5-year survival, but
extending the radiation ﬁeld prophylactically did not yield
greater local control.16 Zhu et al. suggest that at least 50 Gy
should be used for unresectable disease, whereas other stud-
ies show 60 Gy is likely necessary for incompletely re-
sected or gross disease.19,29 Sugie et al.38 suggested adjuvant
mediastinal RT with 30 to 40 Gy for stage II and 50 to 55 Gy
for stage III prevented local recurrence, and low-dose entire
hemithorax irradiation with 11.2 Gy in 7 fractions or 15 to 16
Gy in 10 fractions after removal of disseminated lesions in
the pleura helped to control pleural metastases.
Because thymomas have been shown to be sensitive to
chemotherapy39 as well as RT, multimodality treatment with
preoperative chemotherapy and surgical resection followed
by adjuvant RT has been shown to increase resectability and
FIGURE 1. Sagittal reconstruction of representative thy-
moma showing relationship to vascular structures.
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Author
Masaoka
Stage N Included RT Regimens Dose Speciﬁcation (Gy)
5-Year Local
Control (%)
5-Year Survival
Rate (%)
Cowen et al.10 Preoperative/postoperative
 chemotherapy
22–50 (preoperative)
30–70 (postoperative)
78.5 series 59.5 DFS
I 13 100
II 46 98
III 58 69
IVa 32 59
Curran et al.18 Postoperative (II–IV) 32–60
I4 3
II 21 II–III 79 if
R1/R2
53
III 36 100 if R0 53
IV 3
Forquer et al.15 Postoperative NS
Localized 179 — 81
Regionalized 407 — 76
Haniuda et al.61 Postoperative 40–50
II 70 100 74
III 70 69
Jackson62 II–III 28 Postoperative 32–60 (mean 42) 61 53
Kondo and Monden14 Postoperative  chemotherapy NS
I 552 99.1 100
II 247 95.9 98.4
III 170 71.6 88.7
IV 42 65.7 70.6 (IVa)
52.8 (IVb)
Korst et al.27 Postoperative NS
II 197 75–100 —
III 53 36–100 —
Latz et al.63 Postoperative  chemotherapy 10–72 (median 50)
II 10 81 90
III 14 67
IV 19 30
Mornex et al.29 Preoperative/postoperative
 chemotherapy
30–70 (median 50)
IIIa 21 86 64
IIIb 37 59 (IIIb  IVa) 39
IVa 32
Myojin et al.31 III 32 Preoperative/postoperative 40–60 63 71
Nakahara et al.5 Postoperative 30–50
I 45 — 100
II 33 — 91.5
III 48 — 87.8
IV 15 — 46.6
Pollack et al.64 Postoperative/deﬁnitive 50 (median) 59 (overall)
I1 1 74
II 8 71
III 10 50
IV 7 29
Singhal et al.20 Postoperative 45–55
I 3 100 —
IIa 10 100 —
IIb 10 90 —
(Continued)
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Radiotherapy for Thymic Neoplasms
Copyright © 2010 by the International Association for the Study of Lung Cancer S329survival in patients with stage III and IV thymomas when
compared with surgery alone.35,40,41
Cisplatin, alone or in combination with other agents
(e.g., cyclophosphamide, doxorubicin, vincristine, pred-
nisone, or epirubicin), has demonstrated response rates be-
tween 77 and 100%, pathologic complete response rates
between 4 and 31%, and R0 resections achievable in 57 to
82% of cases. Cohort survival with these multimodality
regimens ranged between 57 and 95%, showing that cispla-
tin-based neoadjuvant chemotherapy, surgery, and adjuvant
RT provides excellent results for those with previously un-
resectable stage III and IV disease.35,40,41
A regimen of combination chemotherapy and deﬁnitive
RT has also provided reasonable results for unresectable
thymomas. A prospective, phase II intergroup study reported
a prolonged progression-free survival in patients treated with
two to four cycles of cisplatin, doxorubicin, and cylcophos-
phamide plus a total dosage of 54 Gy to the primary tumor
and lymph nodes.42 Patients receiving this combination of
therapy had a median survival time of 93 months with a
5-year survival rate of 52.5%.42 A phase II study of a
multidisciplinary approach to the treatment of locally ad-
vanced unresectable malignant thymoma showed that treat-
ment with three courses of induction chemotherapy, surgical
resection, adjuvant RT followed by three courses of consol-
idation chemotherapy provided a 95% survival rate and a
77% progression-free survival rate at 5 years.43
While adjuvant and deﬁnitive RT remain the typical
norm, neoadjuvant RT, although rarely used in the US,
provides another approach to multidisciplinary management.
In addition to neoadjuvant chemotherapy, Onuki et al.44
presented an interesting series of Masaoka stage III thymoma
patients (n  21) involving preoperative RT of 12 to 20 Gy
in conventional fractionation followed by surgical resection 1
to 3 weeks later. The patients were then given a median of 40
Gy (range, 22–66.8 Gy) postoperatively. The series, although
small, evinced impressive survival, with a 5- and 10-year
survival of 91 and 78%, respectively. Patients who achieved
complete resection fared very well, with a 10-year disease-
free survival of 84%.
Adding chemotherapy to neoadjuvant RT, Korst et al.45
are currently recruiting participants for a phase II study
investigating the use of preoperative RT with concurrent
cisplatin and etoposide in patients with thymoma or thymic
carcinoma with signiﬁcant risk of recurrence shown by x-ray
and pathology criteria. In this study, preoperative radiation
will begin 24 hours after the initiation of chemotherapy at a
dose of 4000 to 4500 cGy at 180 to 200 cGy per fraction to
volume including thymus and gross tumor with 2 to 2.5 cm
margin. Three-dimensional conformational or intensity-mod-
ulated radiation therapy techniques will be used to reduce
radiation to nearby structures while delivering higher
doses to the tumor itself. Adjuvant RT will be administered
to selected patients as determined by Masaoka stage at the
time of surgery, WHO pathologic type, and completeness
of resection. Trials such as these are necessary to deter-
mine with exactitude the optimal regimen and sequence of
multimodality management, and enrollment of patients is
heavily encouraged.
RT FOR THYMIC CARCINOMA
Thymic carcinoma is comparatively more rare and
aggressive thymic neoplasm than thymoma with a 5-year
survival of 35%.46 As with thymomas, surgical resection is
the cornerstone of treatment. Prognoses are poor because of
early metastases to the pleura and lung, bone, brain, and liver,
as well as mediastinal, cervical, and axillary lymph
nodes.46,47 Contrasting opinions exist on the role of RT in a
multimodality regimen and combination with speciﬁc chemo-
therapeutic agents. As with the treatment of thymoma, there
is no consensus on an optimum dose or fractionation. Most
studies use a total dose ranging from 40 to 70 Gy with daily
fractions of 1.8 to 2.0 Gy.
Hsu et al.48 analyzed 26 patients given adjuvant RT and
show improved survival and local control with 77% 5-year
TABLE 1. (Continued)
Author
Masaoka
Stage N Included RT Regimens
Dose Speciﬁcation
(Gy)
5-Year Local
Control (%)
5-Year Survival
Rate (%)
Urgesi et al.17 Preoperative/postoperative 39.6–60
III 59 85–90 78
Utsumi et al.28 Postoperative 10–50 (mean 39.3)
I 31 — 77.3 (10-yr OS)
II 43 — 85 (10-yr OS)
III 53 — 79.9 (10-yr OS)
IV 7 — 62.5 (5-yr OS)
Zhu et al.16 Postoperative 45–65
I 47 (60–65 if R1/R2; 50–55
if R0)
96.6
II 41 56.4 96
III 41 42.7 77.8
IVa 32 21.6 56.6
IVb 9 35.6
DFS, disease-free survival; OS, overall survival.
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Author
Patients
in Series Cohort Subcohort N
5-yr Overall
Survival (%)
Median Survival
(mo)
Blumberg et al.21 43 29 65 —
Complete resection Complete resection alone 5 68 —
Complete resection  chemotherapy 3
Complete resection  RT 8
Complete resection  chemoRT 13
Incomplete resection  adjuvant
therapy
Incomplete resection  chemotherapy 1 62 —
Incomplete resection  RT 6
Incomplete resection  chemoRT 6
Hsu et al.48 26 Surgery  RT 77
60 Gy 17 —
60 Gy 9 —
Kondo and Monden14 186 50.5
Surgery alone 24 72.2
Surgery  adjuvant 105 —
Surgery  RT Total resection  RT 46 —
Surgery  chemoRT Total resection  chemoRT 33 73.6
Surgery  chemotherapy Total resection  chemotherapy 41 —
No surgery 24 46.6
RT 18 —
ChemoRT 12 81.5
Chemotherapy 24 24.2
Liu et al.65 38 Completely resected — 15 35
Incomplete resection RT alone 6 14
Chemotherapy 3 21.4
ChemoRT 8 17.3
No adjuvant therapy 4 4.1
Lucci et al.60 7 Induction chemotherapy 
surgery  RT
Complete resection/45 Gy 7 71.4
Incomplete resection/60 Gy 4 71.4
3
Magois et al.54 9 Surgery  RT 1 20
Surgery  chemoRT 2
ChemoRT 1
Chemotherapy 3
Surgery  chemotherapy 2
Maruyama et al.66 25 43 1 3 2
Surgery 3
Surgery  RT/chemotherapy 6
RT 3
ChemoRT 12
Chemotherapy 9
Nakamura et al.67 10 ChemoRT 8 11
Nonaka et al.68 12 Chemotherapy 2 25 24
RT 33 28
No RT 01 2
Ogawa et al.50 40 Surgery Induction chemotherapy 
surgery  RT
6
Surgery  RT  chemotherapy 4
Surgery  RT 17 38
Chemotherapy  RT 10 27
No surgery RT 3 44
60 Gy 15
60 Gy 25
RT, radiotherapy.
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distant metastasis-free rate. Radiation dose was found to have a
signiﬁcant association for local control probability in a small
series consisting of 27 patients with invasive thymoma and 6
patients with thymic carcinoma.49 However, Hsu et al.48 also
found that, although Masaoka staging was a statistically signif-
icant prognostic factor, radiation dose of 60, 60, or 60 Gy
was not a signiﬁcant predictor of overall survival rate.48 Ogawa
et al.50 showed 100% control rates in 40 patients with thymic
carcinoma who underwent complete resection and adjuvant RT
with prescription doses 50 Gy (Table 2).
In a larger multi-institutional series of 186 thymic
carcinoma patients, Kondo et al.14 showed no survival
beneﬁt of adjuvant RT after a subtotal resection. Five-year
survival probability for patients with R0 disease receiving
adjuvant RT was 73.6%, whereas patients receiving adju-
vant chemotherapy, adjuvant chemoradiotherapy, and no
adjuvant therapy had 5-year probabilities of 81.5, 46.6, and
72.2, respectively.14 Although heterogeneous chemothera-
FIGURE 2. Typical anteroposterior
and oblique off-cord boost fields for
conventional three-dimensional
therapy.
FIGURE 3. Axial slices, showing isodose distribution, target volume, and beam geometry for initial anteroposterior fields (left)
and off-cord boost (right).
FIGURE 4. Composite conventional radiotherapy dose–vol-
ume histogram from patient in Figures 1 to 3.
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some explanation for these results, these results are derived
from the largest extant retrospective series and should be
considered by those who advocate adjuvant RT or chemora-
diotherapy for all cases of thymic carcinoma.
Because of the rarity of thymic carcinomas and subse-
quent small numbers of patients treated, it has been difﬁcult to
assess the effectiveness of chemotherapy. Most series have used
cisplatin-based regimens similar to those used in the treatment of
thymoma.51–53 If the treatment of thymoma provides any indi-
cation, it is reasonable to presume that the addition of adjuvant
RT to chemotherapy and surgery might provide additional sur-
vival beneﬁt. While Magois et al.54 have recently presented a
series of nine patients with stage III and IV thymic carcinoma
who showed efﬁcacy of neoadjuvant chemotherapy followed by
surgical resection and adjuvant RT or chemoradiotherapy, others
have suggested that surgery remains the best initial treatment
option for clearly resectable, well-deﬁned disease, and RT
should be added afterward if indicated by information gained by
surgical staging or pathologic study of the surgical speci-
men.14,55 Other studies suggest that neoadjuvant chemotherapy
or RT should be initiated only when thymic carcinoma is
thought to be unresectable.49,56
RT TECHNIQUES
Conventional RT planning typically uses anteroposterior/
posteroanterior ﬁelds, followed by an opposed oblique beam
boost, designed to minimize spinal cord dose (Figures 2–4).
More recently, 3D conformal therapy or intensity-modulated
radiation therapy (Figures 5–8) approaches enable markedly
increased conformality, potentiating dose escalation and/or re-
duction of dose to nontarget organs at risk. When using RT to
treat thymoma and thymic carcinoma, the heart, lungs, esopha-
gus, and spinal cord are at risk and should be the prioritized
organs at risk for dose constraint using reasonable limits derived
from thoracic RT experience. To minimize pulmonary toxicity,
a V20 restriction of 30% and mean lung dose 20 Gy are
advocated based on lung cancer series, with V13 minimized.57,58
The entire heart has been purported to tolerate whole heart dose
FIGURE 5. Positron emission tomography-computed tomography scan of patient with representative 18FDG-avid thymic
carcinoma.
FIGURE 6. Target volume reconstruction showing gross tumor volume (GTV, in red) and planning target volume (PTV, in
yellow) in axial, sagittal, and coronal reconstructions.
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Radiotherapy for Thymic Neoplasms
Copyright © 2010 by the International Association for the Study of Lung Cancer S333of 35 to 40 Gy, allowing no more than one-third of the myo-
cardium to receive 60 Gy.14 It is recommended that the whole
heart dose, if feasible, be kept less than 30 Gy to prevent
coronary arterial disease risk ampliﬁcation.59 Cord doses should
remain 45 Gy. Although earlier reports found grade 3 and 4
toxicity ranging from 11 to 13%,48 newer reports suggest a de-
creased rate of 5 to 10%, potentially due to technical innovations in
RT delivery.50 Death secondary to complications from RT has been
reported in 1 to 13% of cases.60
SUMMARY
Controversy still exists concerning the role of RT in the
treatment of thymic neoplasms. This controversy is unlikely to
be resolved in the near future because of the conﬂicting conclu-
sions of multiple small series and the lack of a large-scale,
prospective, randomized trial. Although such as trial is needed to
give a deﬁnitive algorithm for treatment, low incidence and
indolent course of thymic neoplasms, as well as rapid advance-
ment in the RT technology, currently impede initiation of such
a study. Currently, the role of adjuvant RT in the treatment of
thymic neoplasms largely depends on the stage of disease and
the extent of the surgical resection. Patients with stage I or
completely resected stage II disease do not seem to derive any
appreciable beneﬁt in terms of survival, local control, or recur-
rence on the addition of RT after surgical resection. Thymic
neoplasms with favorable histology such as WHO class A, AB,
and B1 have also been shown not to beneﬁt from adjuvant RT.
In contrast, patients with stage III and IV disease have high enough
recurrence rates that the beneﬁts of RT as part of multimodality
therapy shown in certain studies justify its use despite the existence
of some contrary reports. In addition, patients having undergone a
R1 or R2 extirpation may also beneﬁt from adjuvant RT. More data
are necessary to establish a radiation dose–response relationship as
well as the incidence of toxicity from treatment. It is important to
follow patients indeﬁnitely to monitor for signs of recurrence as
well as late toxicity from radiation. In conclusion, a large-scale,
multicenter, randomized, prospective trial is necessary to develop
evidence-based treatment algorithms for thymic neoplasms.
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